ENSYSCE BIOSCIENCES INC (ENSC)
US2936024056 - Common Stock
Taking everything into account, ENSC scores 2 out of 10 in our fundamental rating. ENSC was compared to 565 industry peers in the Biotechnology industry. The financial health of ENSC is average, but there are quite some concerns on its profitability. While showing a medium growth rate, ENSC is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ENSC has reported negative net income.
In the past year ENSC has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: ENSC reported negative net income in multiple years.
ENSC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ENSC has a worse Return On Assets (-403.45%) than 96.08% of its industry peers.
ENSC's Return On Equity of -623.88% is on the low side compared to the rest of the industry. ENSC is outperformed by 81.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -403.45% | ||
| ROE | -623.88% | ||
| ROIC | N/A |
ROA(3y)-333.3%
ROA(5y)-193.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ENSC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ENSC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ENSC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ENSC has been reduced compared to 5 years ago.
The debt/assets ratio for ENSC has been reduced compared to a year ago.
2.2 Solvency
ENSC has an Altman-Z score of -68.45. This is a bad value and indicates that ENSC is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -68.45, ENSC is not doing good in the industry: 96.26% of the companies in the same industry are doing better.
There is no outstanding debt for ENSC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -68.45 |
ROIC/WACCN/A
WACC9.38%
2.3 Liquidity
ENSC has a Current Ratio of 1.88. This is a normal value and indicates that ENSC is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ENSC (1.88) is worse than 77.18% of its industry peers.
ENSC has a Quick Ratio of 1.88. This is a normal value and indicates that ENSC is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ENSC (1.88) is worse than 76.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 |
3. Growth
3.1 Past
ENSC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.03%, which is quite impressive.
ENSC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -51.75%.
EPS 1Y (TTM)90.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.55%
Revenue 1Y (TTM)-51.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-62.9%
3.2 Future
ENSC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.39% yearly.
The Revenue is expected to grow by 157.05% on average over the next years. This is a very strong growth
EPS Next Y72.48%
EPS Next 2Y35.05%
EPS Next 3Y42.39%
EPS Next 5YN/A
Revenue Next Year-47.5%
Revenue Next 2Y-41.42%
Revenue Next 3Y186.08%
Revenue Next 5Y157.05%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ENSC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENSC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ENSC's earnings are expected to grow with 42.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.05%
EPS Next 3Y42.39%
5. Dividend
5.1 Amount
ENSC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ENSYSCE BIOSCIENCES INC
NASDAQ:ENSC (11/21/2024, 8:24:48 PM)
Premarket: 0.57 -0.02 (-3.78%)0.5924
-0.06 (-9.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap8.83M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -403.45% | ||
| ROE | -623.88% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)90.03%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y72.48%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-51.75%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y